Global Pruritus Therapeutics Market – Analysis and Demand with Forecast Overview to 2029 - by PMI
January 20, 2021 11:05 ET
|
PMI
Covina CA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast...
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors
June 30, 2020 16:45 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
November 14, 2019 16:05 ET
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
Trevi Therapeutics to Present at Stifel Healthcare Conference
November 13, 2019 17:01 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
September 05, 2019 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
June 18, 2019 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
June 13, 2019 16:09 ET
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Trevi Therapeutics Announces Pricing of Initial Public Offering
May 07, 2019 13:22 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...